Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis - Takeaways - MDSpire

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

  • By

  • Paul G. Kemps

  • Jennifer L. Picarsic

  • Sébastien Héritier

  • Jean Donadieu

  • Julien Haroche

  • Laure Farnault

  • Stefania Gaspari

  • Dmitry A. Evseev

  • Daria S. Osipova

  • Alexander E. Druy

  • Milen Minkov

  • Susan Picton

  • Andreas Beilken

  • Robert Möhle

  • Miloš B. Kuzmanović

  • Hitomi S. Okuma

  • Chung W. Chow

  • Martin A. Campbell

  • Gregory S. Phillips

  • Yuhang Zhou

  • Gaurav Goyal

  • Ronald S. Go

  • Kee Kiat Yeo

  • Bryan A. Sisk

  • Joanna L. Weinstein

  • Patrick K. Campbell

  • Eli L. Diamond

  • Jean-François Emile

  • April 14, 2026

  • 0 min

Share

  • 1

    ALK-positive histiocytosis is a rare neoplasm characterized by KIF5B::ALK fusions, often affecting the neurologic system.

  • 2

    In a study of 27 patients, all responded to ALK inhibitors, with 56% achieving complete response and 44% partial response.

  • 3

    Seventy percent of patients discontinued ALK therapy, with 18 maintaining sustained remission and a median treatment-free remission of 1.8 years.

  • 4

    Adverse events occurred in 78% of patients, primarily grade 1 or 2, with manageable complications leading to dose adjustments in some cases.

  • 5

    The study confirms the efficacy of ALK inhibition in ALK-positive histiocytosis, highlighting the potential for long-term remission after treatment cessation.

Original Source(s)

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

  • by Paul G. Kemps, Jennifer L. Picarsic, Sébastien Héritier, Jean Donadieu, Julien Haroche, Laure Farnault, Stefania Gaspari, Dmitry A. Evseev, Daria S. Osipova, Alexander E. Druy, Milen Minkov, Susan Picton, Andreas Beilken, Robert Möhle, Miloš B. Kuzmanović, Hitomi S. Okuma, Chung W. Chow, Martin A. Campbell, Gregory S. Phillips, Yuhang Zhou, Gaurav Goyal, Ronald S. Go, Kee Kiat Yeo, Bryan A. Sisk, Joanna L. Weinstein, Patrick K. Campbell, Eli L. Diamond, Jean-François Emile

  • April 14, 2026

Related Content

Identification of an NFIA::CBFA2T3 fusion in cerebrospinal fluid confirms the diagnosis of pediatric CNS myeloid sarcoma with erythroid differentiation: a case report and literature review

Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report

Ferritin Reference Curves and Optimal Curves in Preadolescent Children